Trial intelligence / Profile preview

Reduced Anticoagulation Targets in Extracorporeal Life Support

NL-OMON22774Not yet recruiting

Sponsor
University Medical Center Groningen
Start
Jan 2020
Modality
Small Molecules, Recombinant Proteins and Enzymes
Countries
1
01

Overview

Randomised, open-label trial of heparin and low molecular weight heparin calcium in heart failure (HF) and respiratory failure (3 arms), sponsored by University Medical Center Groningen. Primary endpoint: Primary composite endpoint. Planned start Jan 2020; status: not yet recruiting.

02

Drugs

heparinlow molecular weight heparin calcium
03

Conditions

heart failure (HF)respiratory failure

Beyond the preview

Go deeper on NL-OMON22774.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON22774.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call